CTNM

Contineum Therapeutics, Inc.

NasdaqGSUSDEQUITY DELAYED

17.19

▲ 1.17 (7.30%)

MARKET · —

Price

Open

16.18

Prev close

16.02

Day high

17.34

Day low

15.88

Volume

353.88K

Market cap

—

P/E (TTM)

—

52W range

8.60 – 17.35

Trailing performance

Price return · vs SPY

Returnvs SPY

+21.14% +22.5%

+19.62% +15.9%

+19.62% +16.5%

+10.33% -0.7%

YTD

+50.39% +38.1%

+93.80% +73.8%

— -74.2%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

15.20

+13.06% from price

SMA 20

15.16

+13.40% from price

SMA 50

14.42

+19.24% from price

SMA 100

13.78

+24.71% from price

SMA 200

13.21

+30.17% from price

EMA 12

15.45

+11.25% from price

EMA 26

15.05

+14.22% from price

EMA 50

14.60

+17.76% from price

RSI (14)

66.4

Neutral

MACD (12,26,9)

0.40

Hist 0.15

ATR (14)

1.10

6.39% of price

Realised vol 30D

62.7%

Annualised

Bollinger upper

16.77

20, 2σ

Bollinger lower

13.55

20, 2σ

50 / 200 cross

Golden

14.42 vs 13.21

Trend bias

Above 200

+30.17%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.06

More volatile than market

Correlation to SPY

0.20

Largely independent

Realised vol 30D

62.7%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-29.8%

Peak to trough

Max drawdown 5Y

-84.4%

Peak to trough

ATR 14

1.10

6.39% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 17.19

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

CTNM · links out to the publisher

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says MT Newswires · 5d ago Morgan Stanley Adjusts PT on Contineum Therapeutics to $18 From $16, Keeps Equalweight Rating MT Newswires · 5d ago RBC Lifts Price Target on Contineum Therapeutics to $23 From $22, Keeps Outperform, Speculative Risk MT Newswires · 22d ago Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones Business Wire · 23d ago Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice Zacks · 44d ago Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry Business Wire · 53d ago Are Medical Stocks Lagging Adagene (ADAG) This Year? Zacks · 81d ago Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference Business Wire · 82d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.